Prostate and mammary cancers are the most common malignant diseases in the Western world and have increased dramatically during the past decade (23). Both cancers are now the second leading cause of cancer deaths in men and women in the United States and their incidences continue to rise. According to recent estimates (23), approximately 317,000 men will be diagnosed with prostate cancer and 41,000 will die of the disease in the United States this year. For women, the cumulative lifetime risk of developing breast cancer is 12%, whereas the lifetime mortality risk has been estimated to be 3.5% (1 1). Despite this serious situation, the etiologies and risk factors for cancer in these organs have remained largely unknown. Some hereditary factors appear to be involved, but other unknown genetic alterations and environmental and life-style factors appear to be the most important causative factors. Although transgenic models for mammary cancer have been developed, no transgenic animal for prostate cancer has been available until recently. Several useful animal models for prostate cancer have been developed using chemical carcinogens (2, 30), but these models are labor intensive and generally require tumor promotion with pharmacologic doses of steroid hormone. Therefore, we developed a transgenic mouse model for prostate cancer by targeting the expression of the simian virus 40 (SV40) early region to the mouse prostate epithelium using the 5' flanking region of the rat C3(1) gene, a gene which is very highly expressed in the rat ventral prostate (20). This was the first reported transgenic model for prostate cancer. Other transgenic mouse models for prostate cancer have also been developed (Table I; see Ref. #7 for review). In addition to the development of prostate cancers, aged male C3( l)/TAg transgenic mice develop tumors of the urethral, bulbourethral, and salivary 'glands, whereas 100% of female transgenic mice develop mammary adenocarcinomas.
EXPERIhlENTAL APPROACH Generation of a transgenic mouse that would develop prostate cancer required the targeted expression of an oncogene to the epithelial cells of the ventral and/or dorsolateral prostate of the mouse. Our strategy was to develop a targeting vector using the rat prostatic steroidbinding protein (PSBP) gene to direct expression of the SV40 large tumor T antigen (TAg) to the prostate. PSBP, also known as prostatein, is the major secretory protein of the rat ventral prostate (22) and is an oligomeric protein composed of the C1, C2, and C3 gene products (22) . Two nonallelic forms of C3 exist-C3(I) and C3(2)but only C3(1) is transcribed (22, 12) . The expression of C3(1) is androgen regulated but not entirely androgen dependent, because endogenous expression in the rat is observed prior to a rise in circulating androgen levels. The C3(1) gene contains several potential androgen response elements (31) . The androgen receptor (AR) gene has been shown to bind to regions upstream of the transcriptional start site and to regions within the first intron and exon (25, 26) .
The early region of SV40 TAg has been used successfully to induce cellular transformation in multiple tissues of transgenic mice (5, 10). Mutations or deletions in p53 and Rb genes appear to be associated with many human cancers, including prostate cancers (13, 18, 14) . Although SV40 TAg is not an etiologic agent in human prostate carcinomas, SV40 TAg functionally inactivates p53 and Rb through the direct binding to these proteins (19). The expression of TAg may, therefore, lead to transformation through mechanisms which are functionally similar to those that occur in the development of human cancers. C3( l)/TAg transgenic mice were generated by microinjecting the recombinant DNA C3( 1)/SV40 TAg fusion construct (expressing both large T and small t antigens) into the pronuclei of 1-day-old mouse embryos (20). Multiple founder lines were generated and analyzed. We have maintained line C for analyses and manipulations.
BIOLOGIC AND CLINICAL CHARACTERISTICS

Prosrare Cnricer
In humans, prostatic intraepithelial neoplasia (PIN) develops in the peripheral zone of the prostate and shares 177 0192-6233/98$3.00+$0.00 178 SHIBATA ET AL TOXICOLOGIC PATHOL~GY (29) and appears very similar to the process proposed to occur in humans.
In the transgenic males (29), low-grade PIN ( Fig. 1B ; wild-type shown in Fig. 1A) is observed in the ventral and dorsolateral prostates at 2-3 mo of age, whereas high-grade PIN (Fig. 1C ) is found in both lobes by 5 mo of age. A progressive increase in the number of PIN lesions was observed with age. Prostate carcinomas ( Fig.  lD) , which appear to arise from PIN lesions, were found by 7 mo of age in the ventral prostate and 11 mo of age in the dorsolateral prostate. The invasion of carcinomas is limited to the surrounding areas of stroma, and no metastases to other organs are seen.
Expression of SV40 TAg protein in these lesions is associated with the development of PIN lesions and carcinomas. Levels of SV40 TAg expression correlates to the levels of p53 expression in these lesions. Levels of cellular proliferation in PIN and carcinomas, as assessed by proliferating cell nuclear antigen (PCNA), are directly related to the degree of seventy of the prostate lesions. Apoptosis levels in the transgenic mice, as has been demonstrated in human prostate cancer, are quite low in normal epithelial cells, moderate in low-grade PIN, and high in high-grade PIN and carcinomas. Eighteen percent of PIN lesions were found to already harbor Ha-ms muta- tions, whereas 33% of carcinomas showed various mutations in Ha-ras, Ki-ras, andor p53. The predominant mutation observed in the prostatic lesions of this transgenic model was a Ha-ras mutation in which there was a CAA to CTA transversion in codon 61 (29) .
Mouse Prostate Carcirionta Cell Lines
Prostate carcinoma cell lines have been established from the prostate carcinomas in the C3( l)/TAg transgenic mice (16). These cell lines are cytokeratin-positive and vimentin-negative, and express SV40 TAg protein. AR expression is only observed at early passage. These cells are nontumorigenic when inoculated into FVB/N mice, but they are tumorigenic when injected into athymic nude mice as well as the C3(l)/TAg transgenic mice. The cell lines can form ductular or acinar structure when grown on Matrigel. Immune cell recognition for a Thl response requires the expression of the major histocompatibility complex (MHC) class I by the cell lines. The prostate carcinoma cell lines we developed express class I H-2s protein, suggesting that these cells may be capable of inducing an immunoresponse and may be useful for immunotherapy studies in this transgenic mouse (16). Metastatic cell lines derived from lung metastasis in nude mice have been also established (Jorcyk et al, in preparation).
Mammary Cancer
Mammary carcinomas in the C3( l)/TAg transgenic females were histopathologically determined to be ductular adenocarcinomas (20, 28), which is the most common histopathologic type of human breast cancer. Multiple mammary tumors develop in all transgenic females by 6 mo of age. Whole mount examination of mammary glands has demonstrated that early atypical hyperplasia originates from intraductular epithelium ( Fig. 2A) . Atypical hyperplasias of the ducts (Fig. 2B ) are noted at 2 mo of age, become nodular lesions by about 3 mo of age (Fig. 2C) , and progress to adenocarcinomas by 4 mo of age ( Fig. 2D ) with invasion into lymph nodes and surrounding tissue. Occasionally, lung metastases ( Fig. 2E , F) are seen at 6 mo of age in about 10% of the females. Most of the female transgenic mice die with mammary cancer between 6 and 7 mo of age.
Expression of SV40 TAg and p53 are associated with lesion development (see Fig. 2F ). Apoptosis levels are significantly higher in atypical hyperplasias and carcinomas as compared to that of normal mammary glands. However, the apoptosis levels in carcinomas are significantly lower than the apoptosis levels in atypical hyperplasias (28) . In order to confirm whether the changes in apoptosis is actually p53-dependent or not, we generated TAg transgenic mice with p53 -/or p53 +/+ by crossing the C3( l)/TAg transgenic mice with p53-knockout mice (15) . Changes in apoptosis of mammary lesions in the TAg transgenic mice with the p53-/genotype are similar to those observed in the C3(1)/TAg transgenic mice with the p53 +/+ genotype, suggesting that the suppression of apoptosis during the transition from preneoplasias to carcinomas occurs via a p53-independent pathway (28) . Although no p53 mutations were found in ex-ons 5-8 (28) , Ha-ras mutations were observed at a low incidence in the mammary lesions.
In order to determine whether the interaction between TAg and p53 was rate limiting in the dev_elopment of the phenotypic change observed in the transgenic mice, we also generated TAg transgenic mice with p53 -/-, p53 +/ -, or p53+/+ genotype as above described. The C3(1)/ TAg transgenic animals with a p53 +/genotype develop much more aggressive mammary tumors, as evidenced by the increased numbers and size of the lung metastasis compared to the C3( 1)RAg animals with both wild-type p53 alleles, suggesting that the functional loss of p53 participates in TAg-induced mammary tumor progression (21). The C3( l)/TAg mice carrying the p53 -/genotype were excluded from this analysis because they died from malignant lymphoma at an early age precluding analysis of metastases.
Maniniary Carciiioriia Cell Lines
Primary and metastatic mammary carcinoma cell lines have been established from mammary carcinomas that developed in the C3( l)/TAg transgenic mice and are currently under investigation. Because the mammary carcinoma cell lines express MHC class I H-2s protein, they may also be useful for immunotherapy studies in this transgenic mouse model.
Other Tumors
The C3( 1)/TAg transgenic males develop adenocarcinomas of the urethral (periurethral) (Fig. 3A) and bulbourethral glands (Fig. 3B) (27) and submandibular gland ( Fig. 3C) (27) . Carcinomas of the urethral and bulbourethral glands are observed in 10-20% of males at about 7 mo of age. Urethral gland carcinoma cell lines Ur12, Ur22, (epithelial) and Ur22, (fibroblastic) have been also established (Jorcyk et al, in preparation) . Adenocarcinomas of the submandibular glands are found in 10% of males at about 8 mo of age and in 60% of males more than 10 mo of age (27) . Mixed tumors of the sweat glands are also observed in both sexes of these transgenic mice ( Fig. 3D) (8) . Occasionally, nasal proliferative or neoplastic lesions develop from the nasal turbinate epithelium (20).
APPLICATIONS AND IhlPLICATIONS
The development of prostate cancer in this transgenic model is very similar to the process that occurs in humans in which PIN lesions appear to develop into invasive carcinomas. The prostate lesions in the transgenic males histologically resemble those found in humans. However, several important differences are apparent between this transgenic model and human prostate cancer, including the fact that prostate tumor metastasis to other organs is rarely seen. Mammary carcinomas in the transgenic females are histopathologically ductular adenocarcinomas, which are the most common histopathologic tumor type in humans.
The C3( l)/TAg transgenic mice are extremely useful for a number of scientific approaches: (a) both prostate and mammary carcinomas, which result in high rates of death and morbidity in humans, can be studied using a the mechanism of cancer development in the urethral and bulbourethral glands, tissues where neoplasms rarely develop in humans; and (e) the carcinoma cell lines that have been developed may be useful for testing immunotherapy strategies against prostate and mammary cancer in C3( l)/TAg transgenic mice.
